Trigemina to Present at the 2013 BIO International Convention
MORAGA, Calif., April 22, 2013 /PRNewswire/ -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced that David C. Yeomans, Ph.D., Chief Scientist and Founder, as well as the Director of Pain Research at Stanford University School of Medicine, will be presenting at the 2013 BIO International Convention's BIO Business Forum on April 22nd, 2013 at the McCormick Place in Chicago, Illinois.
Dr. Yeomans will be providing an overview of Trigemina's lead product candidate, TI-001, an intranasal oxytocin therapy for the treatment of chronic and subacute head pain, and the therapy's patented mechanism of action as it correlates to its overall safety and efficacy. TI-001, which is being evaluated in a Phase 2 clinical study starting patient enrollment in April 2013, has shown promising preclinical and preliminary study results for use as a safe, non-narcotic form of therapy for the effective relief of chronic migraine.
Event: BIO International Convention's BIO Business Forum
Date: Monday, April 22nd, 2013
Place: Chicago Cubs Room at the McCormick Place
Time: 2:00 pm CT
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.
For additional information, please visit www.trigemina.com
About the BIO International Convention
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org
The Ruth Group
Aaron Estrada (media)
SOURCE Trigemina, Inc.